UmbriaExplore our travel guides. Share your stories, tips and questions on Reddit.
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
Unicycive resubmitted the oxylanthanum carbonate (OLC) application on September 29, 2026 with a second drug-product vendor. The company attributes both complete response letters, dated June 27, 2025 and June 29, 2026, to manufacturing deficiencies and reports no efficacy or safety concerns or requests for new clinical data. The new supplier changes the remediation approach; FDA acceptance, manufacturing compliance and approval remain unresolved. June cash resources were $61.4 million, while potential warrant funding is contingent on holders exercising, not automatically delivered by approval.
Get every Merlintrader report in real time on Telegram: join @merlintraderpub_com.
The resubmission went in on September 29, 2026 with a second drug-product vendor, twelve months of stability data from that vendor, and in-vitro bridging data between the two suppliers. The company says it expects acceptance within thirty days and a target action date about six months from resubmission, and that it is retaining both vendors for redundancy. The new vendor’s facility was last inspected in March 2024 with no action indicated — that is the company’s characterisation, not an FDA document this page has read.
In the September 29 release, management said the original vendor had received written notice of an assigned FDA inspection in August, but that the inspection had not yet occurred. That is a dated company statement, not a confirmed inspection appointment or a live FDA status report. The company also intends to seek a shorter review, which the FDA has not committed to provide.
A second vendor, twelve months of stability data and bridging data provide a different route to address the manufacturing deficiencies described by the company. June cash resources and management’s runway guidance into the second half of 2027 provide time to pursue review. A constructive outcome still requires FDA acceptance, satisfactory manufacturing review, approval and commercial execution. Potential warrant proceeds could support funding if holders exercise; they are not committed approval proceeds.
Two review cycles ended in complete response letters about twelve months apart. A vendor change does not establish compliance, and the second letter also called for an integrated safety update while reserving labeling comments. Litigation, financing needs and substantial potential dilution remain. June cash is historical, launch expenditure could differ materially from first-half spending, and neither an approval date nor warrant cash is guaranteed.
At June 30, 2026, Unicycive reported $44.185 million of cash and equivalents and $17.240 million of marketable securities, with no borrowings. First-half operating cash use was $13.845 million; $34.010 million of net ATM proceeds supported the balance. The September 29 resubmission adds a second manufacturer, while management guides that resources fund operations into the second half of 2027. That guidance is not a current cash balance or a precise monthly spending budget.
OLC combines a reduced-pill-burden proposition with unresolved manufacturing review. The September resubmission is the next regulatory test, but acceptance does not establish approval or commercial adoption. Cash resources of $61.425 million were measured at June 30. Preferred warrants can bring additional capital if exercised, with separate milestone-linked expiration dates; potential dilution and proceeds must be modeled together. Two disclosed securities actions add legal uncertainty. The central distinction is between a credible remediation submission and a regulatory outcome that has not yet occurred.
The NDA for oxylanthanum carbonate was resubmitted with a second drug-product vendor, supported by twelve months of stability data from that vendor and in-vitro bridging data between the two. The company expects acceptance within thirty days and a target action date about six months out, and says it is keeping both vendors for redundancy. The same filing reports Meredith S. Manning joining the board effective October 1, 2026, on all three committees and chairing nominating and governance; she was previously chief commercial officer at Soleno. The shares traded 2,306,652 on the day. Form 8-K (SEC) →
The September 28 filing discloses a second securities class action filed September 3 in the Northern District of California. The company disputes the allegations. The older action and derivative proceedings are described in the August quarterly report; that dated filing does not establish their current court status. Form 8-K (SEC) →
The June-quarter report put cash and securities at $61.425 million with no debt, an operating loss of $10.140 million in the quarter and a net loss of only $1.722 million after a $7.977 million non-cash warrant gain. Share count 27,855,257. The same day the company disclosed that the original manufacturing vendor had received written notice that an FDA inspection of its facility had been assigned — and runway guidance of “into 2027,” later upgraded. Form 10-Q (SEC) →
The company reported a second CRL dated June 29, 2026 concerning vendor manufacturing deficiencies. It stated that the agency raised no efficacy or safety concerns and requested no new clinical data. The disclosed response requirements also include a safety update, potential inspections and reserved labeling comments. Form 8-K (SEC) →
How robust or fragile the company looks over the next twelve to eighteen months, scored 1 to 5 across five weighted pillars. Assessed on October 4, 2026, on market data to the September 30, 2026 close.
| Balance sheet and runway · 30% | 3.5 / 5 | June cash and securities totaled $61.425 million; no borrowings were reported. H1 operating cash use was $13.845 million and net ATM proceeds $34.010 million. Management guides into 2H 2027. No current cash balance or exact monthly budget is disclosed. |
| Catalyst · 30% | 3.0 / 5 | Management expects an acceptance response within thirty days of the September 29 resubmission and an action date about six months from resubmission. These are expectations, not FDA-confirmed dates. Two prior reviews ended in CRLs. |
| Dilution · 20% | 2.0 / 5 | The June 30 dilution inventory contained 19,624,727 common-equivalent shares, before the July 2026 IPO-warrant expiration. The warrants were already exercisable; milestones determine their expiration dates. Potential proceeds depend on actual exercise. ATM issuance and preferred conversion increased the basic share count. |
| Liquidity · 10% | 2.5 / 5 | September 30 volume was 862,705 shares versus the dated 63-session average of 917,515. September 15 short interest was 4,202,801 shares and 4.64 days to cover. These historical measures do not guarantee execution liquidity. |
| Execution · 10% | 2.0 / 5 | Two CRLs about twelve months apart and a third submission show unresolved manufacturing execution risk. A second supplier offers an alternative but has not secured approval. Litigation and launch preparation add demands. Manning brings commercial experience; effective internal controls do not resolve FDA compliance. |
This is not an indication to buy or sell. It is a description of financial and operational robustness, not a rating, a target price or a recommendation, and it says nothing about whether the shares are worth their price.
The full deep dive has the answer’s building blocks: cash, dilution, catalysts and risks, every figure sourced.
Free. No signup. You decide, we don’t recommend.
These are reading frames, not forecasts, and none of them is a recommendation. Each is written so that a reader can say which document would confirm or break it.
| Scenario | What it assumes | What would confirm it | What would break it |
|---|---|---|---|
| Bull | The FDA accepts the submission, the second vendor and bridging package satisfy review, and approval supports launch planning. Commercial uptake and reimbursement still need to be demonstrated. Warrant exercises add capital only to the extent holders exercise; the scenario does not assume the entire $100 million arrives at approval. | An FDA-confirmed action date, satisfactory manufacturing outcome, approved label and disclosed exercise proceeds would strengthen this case. | Another CRL, additional manufacturing work, unfavorable label constraints or weaker-than-expected commercial economics. |
| Base | The application proceeds through review while the company funds preparation from existing resources and any financing it chooses to complete. Management’s approximately six-month review expectation remains the planning frame, not a confirmed outcome. Cash use varies with remediation, preparation and legal costs; no exact Q3 cash forecast is implied. | An acceptance disclosure and updated financial statements consistent with management’s runway guidance. | A materially longer review, a major expenditure change or financing terms that alter per-share economics. |
| Bear | The alternative vendor does not resolve all FDA requirements, delaying revenue and increasing funding needs. Litigation consumes management time and resources, and further equity issuance dilutes holders. Potential warrant proceeds may not arrive when needed. | A further CRL or extension, deteriorating cash guidance, unfavorable litigation developments or substantial discounted issuance. | Satisfactory manufacturing review, approval, adequate funding and evidence of viable launch economics. |
The constructive scenario is a hypothesis about successful remediation, not a finding that the factory problem has been solved. Manufacturing quality is part of the drug approval standard. An absence of reported efficacy objections narrows the disclosed issue but cannot eliminate the agency’s remaining review responsibilities.
The assessment rests on a disclosed manufacturing problem, a submitted remediation package and a cash balance that predates the latest filing. These are the observations that would change its weight.
These are conditional tests of the assessment, not forecasts or investment instructions.
UNI-494 is licensed from Sphaera Pharma Pte. Ltd. and is a prodrug cleaved by esterases to nicorandil; the annual filing describes selective activation of the mitochondrial KATP channel’s SUR2B subunit. OLC’s Renazorb program and related rights were acquired from Spectrum Pharmaceuticals in September 2018. These clarify asset identity and provenance without establishing clinical efficacy. Primary source 1. Primary source 2.
OLC is a lanthanum-based phosphate binder intended for hyperphosphatemia in adults with chronic kidney disease on dialysis. In the published Phase 2 trial, 86 patients received treatment and 78 entered maintenance; 71 of those 78 achieved phosphate control during titration. Thus the reported 91% is not 91% of all 86 treated patients. Among the 71 achieving control, 49 (69%) did so with three tablets a day or fewer. Three of 86 patients (4%) discontinued because of treatment-related adverse events. These denominators distinguish the tolerability population from the efficacy-evaluable subset.
The company calls UNI-OLC-201 its pivotal tolerability study. The September 29 release describes three clinical studies supporting the NDA: Phase 1 and bioequivalence studies in healthy volunteers, and a tolerability study in patients with CKD on dialysis. The registration strategy uses the 505(b)(2) pathway, but this does not make the Phase 2 study non-pivotal or show that efficacy and safety are outside FDA review. Its open-label, single-arm design and short follow-up limit comparisons with other binders. The primary objective was tolerability at clinically effective doses, not a randomized superiority test.
The competitive setting includes established phosphate binders such as sevelamer and ferric citrate, plus tenapanor, which reduces intestinal phosphate absorption through a different mechanism. A lower tablet burden is a potential convenience advantage rather than proof of superior long-term adherence or outcomes. In U.S. dialysis, reimbursement and provider adoption matter separately from FDA approval. TDAPA is a CMS payment pathway, and its approval is a separate milestone used to define one warrant tranche’s expiration.
The second programme is UNI-494, a nicotinamide ester that activates mitochondrial ATP-sensitive potassium channels, aimed at acute kidney injury and delayed graft function, past a Phase 1 in healthy volunteers and holding orphan designation for delayed graft function. It is not a 2026 catalyst.
| Date | Event |
|---|---|
| August–September 2024 | NDA submitted; FDA receipt date August 28, 2024 |
| November 2024 | Application accepted for review |
| June 10, 2025 | Company discloses current good manufacturing practice deficiencies at a third-party vendor |
| June 27, 2025 | First complete response letter, announced June 30: manufacturing deficiencies according to the company |
| October 28, 2025 | Type A meeting update: a single deficiency, turning on the vendor’s compliance status |
| December 29, 2025 | Resubmitted, on the company’s belief that the original vendor had progressed to inspection readiness |
| January 29, 2026 | Resubmission accepted, Class 2 review, target action date June 29, 2026 |
| June 29, 2026 | Second complete response letter, announced June 30 — same vendor deficiencies; reinspection never conducted during the review |
| August 12, 2026 | Company disclosed that an inspection had been assigned; the September 29 release said it had not yet occurred |
| September 29, 2026 | Resubmitted with a second drug-product vendor, twelve months of stability data, in-vitro bridging data; both vendors retained; acceptance expected within thirty days |
What the second letter actually requires, which is more than a vendor swap. The FDA letter itself lists: satisfactory responses on current good manufacturing practice; an FDA compliance determination; possible reinspection; a possible pre-approval inspection; an integrated safety update; and comment on labelling reserved. Changing supplier is intended to address manufacturing deficiencies, but satisfactory FDA assessment remains necessary. The safety update and the labelling comment are separate work that acceptance of the resubmission does not dispose of. FDA June 29, 2026 complete response letter
And note what the September 29 filing did with its own most forward-looking sentence. The Form 8-K incorporates the press release “except for the fourth paragraph therein” — and that paragraph is the one describing the original vendor’s assigned-but-not-conducted inspection and the company’s intention to seek a shorter review timeline. Management kept it outside the incorporated disclosure, which is a drafting choice worth noticing rather than an allegation of anything.
The reviewed company disclosures do not identify either manufacturer by name. The second facility’s March 2024 no-action-indicated inspection classification is attributed to management; this review has not independently matched it to a specific FDA inspection record. A historical facility inspection is not approval of the current OLC application.
| Item | June 30, 2026 |
|---|---|
| Cash and cash equivalents | $44.185M |
| Marketable securities (corporate bonds) | $17.240M |
| Combined | $61.425M |
| Total assets / total liabilities | $72.029M / $18.759M |
| Of which warrant liability (non-cash, level 3) | $13.718M |
| Total stockholders’ equity | $53.270M |
| Accumulated deficit | $142.370M |
| Debt | None. Liabilities are payables, accruals, the warrant liability and a $0.671M lease |
The cash trail on the disclosed dates: $41.269M at December 31, 2025; $57.1M as of the May 11, 2026 first-quarter release; $61.425M at June 30, 2026. The balance went up over the half because the at-the-market programme raised $34.0 million net, not because the business consumed less.
Burn. Operating cash use was $13.845 million over the first half of 2026 — $2.31 million a month, against $17.323 million in the first half of 2025. For the full year 2025 it was $31.317 million, about $2.61 million a month. So the rate has come down.
Runway: take the guidance, and note the gap. On August 12, 2026 the company said its resources would fund operations “into 2027”; on September 29 it upgraded that to “into the second half of 2027” — an upgrade, which is unusual and worth printing.
Dividing $61.425 million by first-half average operating cash use of $2.3075 million per month gives about 26.6 months from June 30. This is a static historical quotient, not a cash forecast. Management’s phrase “into the second half of 2027” has no precise endpoint, so it cannot establish an eighteen-month runway or an implied $3.4 million monthly budget. Future manufacturing, launch preparation and legal spending may change cash use, but their contribution to the difference is not quantified in the release.
There is no September 2026 cash figure. The resubmission release of September 29 restates the June 30 balance; it does not update it. The next disclosure is the third-quarter report, due around mid-November.
The June quarterly report concludes that anticipated resources support operations for at least one year after financial-statement issuance without substantial doubt. This is management’s dated going-concern assessment, not a guarantee that additional capital will be unnecessary. The annual report also concluded that internal control over financial reporting was effective at December 31, 2025. Neither conclusion removes the separate regulatory and commercialization risks.
In Q2, research and development expense was $2.788 million and general and administrative expense $7.352 million, producing a $10.140 million operating loss. The $1.722 million net loss reflects a $7.977 million non-cash warrant remeasurement gain and $0.441 million interest income. Warrant valuation can change with share prices and other assumptions; the gain is not operating revenue or cash funding. Operating performance and cash flow therefore provide different information from the reported net loss.
For scale on the prior year: the 2025 net loss was $26.6 million against $36.7 million in 2024, with an accumulated deficit of $127.8 million at the end of 2025 and $142.370 million six months later.
The share-count bridge separates sales for cash from conversion of securities already outstanding.
| Cover date | Shares outstanding |
|---|---|
| August 14, 2025 | 17,661,698 |
| November 12, 2025 | 21,491,396 |
| December 31, 2025 | 22,114,245 |
| March 30, 2026 | 25,237,782 |
| June 30 and August 12, 2026 | 27,855,257 |
That is up 58 per cent in twelve months, and all of it on the same basis, because the 1-for-10 reverse share combination took effect on June 20, 2025 — certificate of amendment June 18, split-adjusted trading from the open on June 20 — before the first row in this table. Per-share data in the filings is restated retroactively; the authorised count and par value were unchanged. Any chart, price target or per-share figure quoted from before June 20, 2025 is on a pre-combination basis.
The Guggenheim ATM sold 5,278,767 shares in the first half at an average $6.64, generating $35.062 million gross and $34.010 million after $1.052 million commissions. The equity statement separately records conversion of Series A-2 Prime preferred into 462,245 common shares. Starting with 22,114,245 shares at December 31, these two movements reconcile to 27,855,257 at June 30. ATM proceeds account for first-half financing cash flow; preferred conversion accounts for additional shares without equivalent new cash. The June report does not establish subsequent ATM use.
A detail about the shelf that is widely misstated. The registration statement filed June 5, 2026 and effective June 15 registers a $150 million base shelf, and within it a sales-agreement prospectus covering $50 million of common stock for the Guggenheim programme. The sales agreement itself is written for up to $150 million “subject to certain limitations.” So the contractual ceiling and the currently registered tranche are different numbers: $150 million of shelf, $50 million of registered at-the-market capacity, with unsold portions reverting to the base prospectus if the agreement terminates.
| Instrument | Common-equivalent shares | Terms |
|---|---|---|
| Preferred warrants, Tranches A, B and C | 15,818,817 | Weighted-average common-equivalent exercise price $6.41 in the Q2 table. Approximately $100M potential aggregate proceeds, conditional on exercise. Milestones define expiration, not the start of exercisability; details below. |
| Stock options | 1,968,914 | Weighted-average exercise price $8.38, 7.71 years remaining; 1,038,929 vested at a $10.31 average. $13.5M of unrecognised cost over about three years |
| Restricted stock units | 1,358,577 | May 2026 grants of 1,270,700 to executives and 84,200 to directors at a $8.56 grant-date fair value; the 10-Q summarizes executive vesting over three years and director vesting over one year; individual grant schedules differ and control |
| Common stock warrants | 478,419 | Historical June 30 IPO-warrant inventory, including warrants issued on earlier note conversion; the IPO warrants expired in July 2026. |
| Total potentially dilutive | 19,624,727 | Illustration combining June award inventory with 27,855,257 basic shares: about 47.5 million before the July IPO-warrant expiry; not a current fully diluted share count. |
The three preferred-warrant tranches were exercisable from their original issuance date under the amended agreements. Their milestone-linked 21-day periods determine expiration: FDA approval for Tranche A, TDAPA approval for Tranche B, and disclosure of four quarters of commercial sales following TDAPA for Tranche C. These are not windows that first permit exercise after approval.
The company describes approximately $100 million of potential exercise proceeds across the three tranches. Cash receipt depends on actual exercises and contractual terms. Approval alone neither deposits $100 million nor converts every potentially dilutive security. The June 30 capitalization table is a scenario inventory, not a forecast of the share count immediately after approval.
The amended contracts define exercisability from the original issuance date, July 11, 2023. They expire after the relevant milestone-linked periods, subject to contractual provisions including fundamental-transaction treatment. For Tranche C, the milestone is public disclosure of financial results for four quarters of commercial sales following TDAPA approval, with the first quarter measured when CMS revenue begins under TDAPA. Approximately $25 million, $25 million and $50 million of potential proceeds are associated with A, B and C respectively. Approval alone does not supply the combined $100 million. Holders must exercise, and conversion and ownership limitations can affect the timing of common-share issuance. A valuation scenario should state which tranche is exercised and include only its associated cash and shares.
Authorized capital includes 400 million common shares at $0.001 par and 10 million preferred shares. No designated preferred shares were outstanding at June 30 after the disclosed conversions. Authorized but unissued stock provides legal capacity, not an assurance of access to financing on attractive terms. The 2021 plan reserve increased by 884,570 shares under its 4% evergreen provision on January 1, 2026; approximately 904,019 remained available for grant at June 30. Plan capacity is distinct from issued shares and unvested awards already included in the dilution table.
The annual report’s $64.310 million non-affiliate market value is measured at June 30, 2025. It should not be treated as today’s public float or as a current ATM allowance. Form S-3 eligibility and the smaller-issuer one-third limitation depend on the applicable float measurement and offering history. The shelf, sales-agreement ceiling and amount registered in the ATM prospectus are separate constraints; unused contractual capacity alone does not establish how much can be sold today.
On March 12, 2026, a purported shareholder demanded that the board bring claims against current and former officers and directors. On March 30, the board deferred a final decision while the securities and derivative actions remained pending. Separately, the September 28 filing discloses another securities class action filed September 3. These are allegations and procedural developments, not judicial findings against the company. Primary source 1. Primary source 2.
The legal disclosures concern separate proceedings. Allegations are not adjudicated findings, and the absence of a recorded loss does not establish that exposure is zero.
The June quarterly report describes Elkhodari v. Unicycive Therapeutics, No. 3:25-cv-06923-JD, filed August 15, 2025 in the Northern District of California for a March 29, 2024–June 27, 2025 class period. The company states that dismissal briefing concluded May 27, 2026. It also describes derivative actions consolidated April 30 and stayed by order dated July 29 pending the dismissal decision. Those statements are from the report filed August 12; this page does not independently certify the court docket’s current status.
A future dismissal decision could change the litigation burden, but its implications depend on the order, possible amendment and appeal rights. A denial would not by itself quantify damages or dictate every subsequent discovery step. The filings do not provide a reliable date for the decision. Investors should look for the actual court order or a subsequent company disclosure rather than infer closure from a quiet news period.
A second securities class action was filed September 3, 2026, also in the Northern District of California, over statements about the OLC application, and was disclosed in an Item 8.01 Form 8-K on September 28, 2026. The company calls the claims meritless. Again, no accrual and no estimate.
A chain of filings that is individually unremarkable and collectively worth printing. Gaurav Aggarwal signed the annual report as a director on March 30, 2026, and resigned from the board on April 6, 2026 — a week later. The Form 8-K states expressly that the resignation was not the result of any disagreement on operations, policies or practices.
A July 1, 2026 Form 144 by Vivo Opportunity Fund Holdings notified an intended sale of 1,789,916 shares, with an approximate sale date of June 30 and stated market value of $9,450,756. A Form 144 is a proposed-sale notice, not confirmation of execution. Its relationship to the former director and timing are disclosed ownership context; they do not establish motive, a completed disposition or whether every subsequent reporting obligation applied.
Shalabh Gupta is chief executive. Meredith S. Manning joined the board effective October 1, 2026 and serves on the audit, compensation, and nominating and governance committees, chairing the latter. The company highlights her previous commercial leadership, including at Soleno. That experience is relevant to prospective launch planning but is not evidence of an established dialysis-channel commercial record or successful OLC launch.
The reviewed 2026 Forms 4 primarily concern May 14 equity awards and later amendments rather than identifiable open-market purchases or sales. An absence of a reported transaction in this set is not proof that no insider transaction occurred. SEC submissions also include Manning’s initial Form 3 filed October 1, so it would be incorrect to say nothing has been filed since July. The CEO grant’s individual Form 4 footnote and the quarterly report’s aggregate description use different vesting language; use the award-specific filing for that grant rather than assume all executive awards follow one schedule.
| Metric | Value |
|---|---|
| Close, September 30, 2026 | $4.695, up 3.19 per cent from $4.55 |
| Session range, from a $4.61 open | $4.5743–$4.81 |
| Volume | 862,705, against a 63-session average of 917,515 — 0.94 times |
| The resubmission session, September 29 | 2,306,652 shares |
| Week / month / quarter | −2.4% / −9.7% / −11.1% |
| Twelve months | +13.1 per cent, against $4.15 a year earlier |
| Market value, basic | $130.8M on 27,855,257 shares |
| Historical gross-dilution sensitivity | About $223M at the stated price using the pre-July-expiry 47.5M illustration; not current market capitalization or GAAP diluted shares. |
| Institutional ownership | 44.51 per cent, 12,399,330 shares, 87 holders |
The institutional detail is unusually one-sided: 58 holders increased positions by 5,940,685 shares and 36 opened new ones totalling 1,320,759, against 19 reducing by 4,106,326. That is net accumulation across the period those filings cover — with the standard caveat that this data comes from quarterly position reports in arrears, and the provider does not state an as-of date, so it should be read as the latest reported round rather than as a current position.
| Settlement date | Short interest | Average daily volume | Days to cover |
|---|---|---|---|
| September 15, 2026 | 4,202,801 | 905,197 | 4.64 |
| August 31, 2026 | 3,910,813 | 668,814 | 5.85 |
Two things to get right here. First the date: the most recent published settlement is September 15, 2026, not September 30. Short-interest data appears roughly on the eighth business day after settlement, so a figure presented as of quarter-end does not exist yet.
The September 15 short position equals 15.09% of the 27,855,257 outstanding shares used here. It increased approximately 7.5% from August 31. Both settlements precede the September 29 resubmission, so they do not measure short sellers’ response to that announcement. Days to cover is short interest divided by an average volume measure, not a deadline by which positions must close. Changing the volume period changes the result; it is not evidence of a different short position.
No current analyst consensus target is published here because the provider fields reviewed were inconsistent and could not be reconciled to dated original research. The inconsistency does not prove which feed value is wrong or why. A usable target needs a named analyst, firm, publication date and split-adjusted basis. Company-sponsored research should be identified as such and assessed separately from independent coverage.
| Window | Event | Status |
|---|---|---|
| By about October 29, 2026 | Acceptance of the third NDA resubmission — the company expects a decision within thirty days of the September 29 filing | Company expectation. The nearest dated event |
| About six months from September 29 resubmission | Target action date on the resubmitted application, which on the company’s own framing puts it around the end of the first quarter of 2027 | Company expectation; the review class has not been confirmed in a filing |
| Not dated | Original vendor inspection: assignment disclosed in August; not conducted as of the September 29 company statement. | Company-reported status; no current FDA appointment verified. |
| Not dated | Potential ruling in the 2025 securities action. | Briefing and derivative stay described in the August quarterly filing; current court status not independently certified. |
| Q3 reporting cycle, expected around mid-November | September 30 financial statements, subsequent financing and updated legal disclosures. | Estimated reporting window; not a confirmed earnings announcement date. |
| 21 days after FDA-approval announcement | Contractual expiration milestone for Tranche A preferred warrants. | Already exercisable under amended terms; potential proceeds require exercise. |
| After later commercial milestones | Tranche B expiration follows TDAPA approval; Tranche C follows disclosure of four quarters of commercial sales after TDAPA. | 21-day expiration periods; not commencement of exercise. |
| January 2027 plan cycle | Potential reserve increase under the equity plan evergreen provisions. | Plan terms determine the increase; reserve capacity is not issued stock. |
None of the above is a recommendation, a target or a view on the share price. It is a description of what is documented, what is guided, and what the record does not say.
Method and limits. Financial and capitalization figures come from the June 30 10-Q and annual report. Warrant timing is checked against the amended A, B and C contracts, including the definition of exercisability and expiration. Clinical denominators come from the published trial. September 28 and 29 SEC filings and the latest SEC submissions index were checked on October 4. Market figures retain their September 30 or September 15 dates. Manufacturer inspection statements are attributed to management; no manufacturer-specific FDA record or current court docket is independently certified. Potential proceeds, dilution inventories and historical cash quotients are distinguished from actual cash or forecasts.
Balance-sheet and income-statement figures are those reported for the quarter ended June 30, 2026 and are historical. Price, range, volume and performance figures are at the September 30, 2026 close. A 1-for-10 reverse share combination took effect on June 20, 2025, so prices and per-share figures from before that date are on a different basis unless adjusted. Short-interest figures are as of the September 15, 2026 settlement date and are published with a lag. Institutional-ownership figures derive from lagged quarterly filings. Market prices are indicative and may differ materially from the opening or closing price on any given day.
Additional primary verification: Amended Tranche A warrant; amended Tranche B warrant; amended Tranche C warrant; published OLC Phase 2 trial. Contracts distinguish exercisability from milestone-linked expiration. The clinical publication specifies the denominators and safety population.
FDA June 29, 2026 complete response letter (primary redacted document)
According to the company, both complete response letters concerned manufacturing deficiencies at a third-party vendor and neither raised efficacy or safety concerns or requested new clinical data. Manufacturing quality is part of the regulatory assessment. The FDA letter also requires an integrated safety update and reserves labeling comments; the letters should not be described as proving approval of every other aspect of the application.
The September 29 submission adds a second drug-product vendor, supported by twelve months of stability data and in-vitro bridging data. Management reports a March 2024 no-action-indicated inspection for that facility and intends to retain both suppliers. The original vendor’s assigned inspection had not occurred as of that release. Neither historical inspection status nor submission establishes current FDA acceptance or approval.
Acceptance would confirm that the FDA has accepted the response for review. It would not establish a favorable decision. Management expects an action date about six months from the September 29 resubmission; the actual FDA date and classification should be taken from the acceptance disclosure. Manufacturing compliance, the integrated safety update and labeling remain relevant.
$61.425 million at June 30, 2026 — $44.185 million of cash and equivalents plus $17.240 million of corporate bonds — and no debt. Operating cash use was $13.845 million over the first half, about $2.31 million a month. The company guides that this funds operations “into the second half of 2027”, upgraded from “into 2027” in August. There is no going-concern qualification: the filing states there is “not substantial doubt” about continuing operations. No September 30 cash figure has been disclosed.
At June 30 the reported potentially dilutive inventory was 19,624,727 common-equivalent shares against 27,855,257 outstanding. Adding them gives about 47.5 million, or 70.5% more, as an illustrative maximum inventory before considering exercise, vesting and conversion conditions. Preferred-warrant expiration dates are linked to FDA approval, TDAPA and later sales reporting. They were already exercisable under the amended contracts. Approval does not automatically issue all these shares or deliver all potential proceeds.
The reviewed disclosures identify two securities class actions, plus derivative litigation. The 2025 securities action and derivative stay are described in the August 12 quarterly report; the new September 3, 2026 action is disclosed in the September 28 8-K. These filing dates bound the available status information. No recorded loss is not the same as no possible liability, and the current court docket has not been independently certified here.
Yes, and it is routinely left out. A 1-for-10 reverse share combination took effect on June 20, 2025, with the certificate of amendment filed June 18. Per-share data in the filings has been restated retroactively, and the authorised share count and par value were unchanged. Any price, chart, target or per-share figure quoted from before that date is on a different basis.
This page does not publish a current consensus target because conflicting provider fields were not reconciled to original dated analyst notes. There is no basis to attribute the discrepancy confidently to a particular CRL or feed-reset error. An individual target should be checked for its date, source and treatment of the June 2025 reverse split before comparison with the current price.
4,202,801 shares at the September 15, 2026 settlement date — 15.09 per cent of the 27,855,257 shares outstanding, or about 15.79 per cent of a float near 26.6 million, with 4.64 days to cover. That is up 7.5 per cent from 3,910,813 at the August 31 settlement. There is no September 30 figure: short-interest data is published roughly on the eighth business day after settlement.
No. This Stock Hub is informational and educational. It sets out dated facts, their sources and the scenarios they leave open, and it says where the record is silent. It does not recommend any action, and the outcome of a regulatory review is not knowable in advance.
Every Merlintrader stock hub, catalyst update and market brief is published to Telegram the moment it goes live. No paywall, no spam, just the research.
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent analysis and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $UNCY or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, official trial registries and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single decision can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
Educational and editorial content only. This report is not personalised financial advice, a solicitation, or a recommendation to buy, sell or hold any security. Biotech and small and mid-cap stocks can be extremely volatile and may result in partial or total loss of capital. Regulatory outcomes, manufacturing inspections, litigation, financing availability, dilution and commercial execution all remain uncertain.
